Clinical trials: PET/MRI
Glioblastoma Multiforme, Glycolytic Index
Biologic Association Between Metabolic Magnetic Resonance-positron Emission Tomograph (MR-PET) and Tissue Measures of Glycolysis in Brain Tumors of Infiltrating Glioblastoma Cells
The purpose of this project is to validate a new combined MRI and PET imaging technique as a biomarker or measure of glycolysis in brain tumors.
- Conditions
- Glioblastoma Multiforme, Glycolytic Index, Epidermal Growth Factor Receptor
- Trial name
- NCT06059690
- Testing
- pH Measurement of in vivo tissue
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Anal Cancer
Predictive Value of FMISO-PET, FDG-PET-CT, DWI-MRI and DCE-MRI Scans for Patients With Anal Cancer Receiving Radiotherapy +/- Chemotherapy
The purpose of the study is to evaluate the predictive value of 18F-fluoromisonidazol-PET (FMISO-PET), 2-18F-fluoro-2-deoxy-d-glukose-PET-CT (FDG-PET-CT), Diffusion-Weighted Magnetic Resonance Imaging (DWI-MRI) and Dynamic…
- Trial name
- NCT01330186
- Testing
- FMISO-PET, FDG-PET-CT and Magnetic Resonance Imaging (MRI)
- Where
- Denmark
- Volunteers
- 50 people
- Sponsor
- Copenhagen University Hospital at Herlev
Knee Injury
F18-Flouride PET/CT in Acute Knee Injury
18F-fluoride is a positron-emitting bone-seeking agent with favorable pharmacokinetic properties. Its uptake mechanism resembles that of 99mTc-MDP.
- Trial name
- NCT00687921
- Volunteers
- 50 people
- Sponsor
- Tel-Aviv Sourasky Medical Center
Rectal Cancer
Prediction of the Response to Neoadjuvant Radiation Chemotherapy Through Texture Analysis Derived From Medical Imaging
In patient with complete pathological response, surgery could be omitted without compromising progression-free or overall survival. A powerful prediction model is needed to guide management of this population.
- Trial name
- RECTOMICS (NCT04920435)
- Where
- 3 sites in France
- Volunteers
- 124 people
- Sponsor
- University Hospital, Brest
Glioblastoma
Early Diagnosis of Pseudoprogression Using 11C-Methionine PET-MRI After Concomitant Radiochemotherapy Treatment for Glioblastoma.
Pseudoprogression is a phenomenon related to post-treatment rearrangements (including radiation necrosis). It appears early in the first year after treatment and accounts for 30 to 50% of patients followed with glioblastoma.
- Trial name
- TIGRE (NCT03739333)
- Testing
- 11C-Methionine PET-MRI
- Where
- France
- Volunteers
- 40 people
- Sponsor
- Hospices Civils de Lyon
Locally Advanced Rectal Cancer (LARC)
Application of PET/MRI in the Evaluation of the Efficacy of Neoadjuvant Therapy for Locally Advanced Rectal Cancer
This study plans to include LARC patients receiving neoadjuvant therapy at this center, conducting PET/CT and PET/MR examinations before treatment, and PET/MR examinations before surgery after neoadjuvant therapy.
- Trial name
- NCT06653452
- Testing
- 18F-FDG PET/CT and PET/MR scan, 68Ga-FAPI-04 PET/CT and PET/MR scan
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Peking Union Medical College Hospital
Brain Diseases, Covid19
Pilot Study for PET/MR Imaging of Covid-19
The primary goal of this project is to study the feasibility of a prototype brain-dedicated PET insert for an MR scanner for simultaneous acquisition of PET/MR images of metabolism and perfusion in Covid-19 negative and…
- Trial name
- NCT04954248
- Testing
- Injected radiotracer with PET Insert
- Where
- United States
- Volunteers
- 3 people, healthy volunteers welcome
- Sponsor
- Stanford University
Prostate Cancer
68Ga-PSMA PET/MRI in Conjunction With mpMRI for Evaluating Prospective Prostate Cancer Risk
The goal of this observational study is to learn if Ga-68 PSMA PET/MRI can better diagnose prostate cancer than mpMRI in males between 40 to 85 years old who is naive to prostate biopsy and is suspicious for prostate cancer by…
- Trial name
- NCT06494696
- Testing
- Ga-68 PSMA PET/MRI
- Where
- Taiwan
- Volunteers
- 71 people, healthy volunteers welcome
- Sponsor
- Chang Gung Memorial Hospital
Prostate Cancer, Advanced Prostate Cancer
European Registry of Next Generation Imaging in Advanced Prostate Cancer
The RING study is a European registry collecting real-world data on advanced prostate cancer (APC) imaging. It aims to evaluate the role of next-generation imaging (NGI), such as PET/CT and whole-body MRI, in detecting and…
- Conditions
- Prostate Cancer, Advanced Prostate Cancer, Metastatic Prostate Cancer (mPC)
- Trial name
- RING (NCT06866782)
- Testing
- Imaging
- Where
- 24 sites in Belgium, France and 6 more
- Volunteers
- 600 people
- Sponsor
- Fundacio Puigvert
Brain Tumor
PET (FDG)-MR Imaging for the Adult Patients Presented With Brain Tumor
Background and purpose: In adult, the half of the CNS neoplasms are metastatic, and high grade astrocytomas and oligodendrogliomas are most frequent malignant tumors among the last half.
- Trial name
- NCT02071017
- Where
- South Korea
- Volunteers
- 6 people
- Sponsor
- Seoul National University Hospital
Posttraumatic Stress Disorder, Traumatic Brain Injury
Mild Traumatic Brain Injury and Post-Traumatic Stress Disorder
Background: Some people who have a traumatic brain injury (TBI) recover completely. Others, however, develop post-traumatic stress disorder (PTSD), with anxiety and depression.
- Trial name
- NCT01547819
- Volunteers
- healthy volunteers welcome
- Sponsor
- National Institutes of Health Clinical Center (CC)
Progression of Prostate Cancer
FOcal RECurrent Assessment and Salvage Treatment
Radiotherapy is the commonest form of prostate cancer treatment in the UK. In one in four men, radiotherapy will fail to control the cancer. These men are offered hormonal treatment which has significant side effects.
- Trial name
- FORECAST (NCT01883128)
- Testing
- Whole Body MRI, Focal Salvage Therapy, MRI Targeted biopsies
- Where
- 2 sites in United Kingdom
- Volunteers
- 177 people
- Sponsor
- University College London Hospitals
Breast Cancer
Evaluation of Data Obtained From Three Common Imaging Techniques: Positron Emission Tomography (PET-CT), Breast Ultrasound, and Magnetic Resonance Imaging (MRI) After Neoadjuvant Chemotherapy in Patients With Breast Cancer
Breast cancer is the most common and most deadly malignant tumor in women. In the case of invasive breast cancer, cancer cells have invaded the tissues surrounding the tumor.
- Trial name
- NCT07441330
- Testing
- Breast ultrasound, MRI, TEP-TDM
- Where
- France
- Volunteers
- 42 people
- Sponsor
- GCS Ramsay Santé pour l'Enseignement et la Recherche
Healthy, Hyperalgesia
Positron Emission Tomography to Measure Pain and Pain Control
This study will examine how the brain processes pain signals and how the different parts of the brain work with each other in response to painful stimuli.
- Conditions
- Healthy, Hyperalgesia, Pain, Peripheral Nervous System Disease
- Trial name
- NCT00001307
- Testing
- Oxygen-15 Water, Capsaicin
- Where
- United States
- Volunteers
- 273 people, healthy volunteers welcome
- Sponsor
- National Institute of Dental and Craniofacial Research (NIDCR)
Male Breast Cancer, Stage II Breast Cancer
FDG PET and DCE-MRI in Predicting Response to Treatment in Patients With Breast Cancer
This clinical trial studies fludeoxyglucose F 18 (FDG) positron emission tomography (PET) and dynamic contrast-enhanced (DCE)-magnetic resonance imaging (MRI) in predicting response to treatment in patients with breast cancer.
- Conditions
- Male Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer
- Trial name
- NCT01931709
- Testing
- fludeoxyglucose F 18, positron emission tomography, dynamic contrast-enhanced magnetic resonance imaging
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- University of Washington
Alzheimer Disease
Exploratory Study of Low-Dose Whole-Brain Radiation Therapy With HeLaXON 1X in Patients With Mild Alzheimer's Disease Dementia
This randomized, sham-controlled, exploratory clinical trial will evaluate the efficacy and safety of HeLaXON, an investigational low-dose radiation therapy device, in patients with mild Alzheimer's disease dementia.
- Trial name
- LDRT-AD-03 (NCT07863011)
- Testing
- HeLaXON 1X Low-Dose Radiation Therapy
- Where
- South Korea
- Volunteers
- 30 people
- Sponsor
- ReadyCure Inc.
Glioma
Multiparametric Metabolic and Hypoxic PET/MRI Imaging Substudy in Gliomas
This substudy will investigate a new imaging approach using positron emission tomography (PET) and two investigational drugs ([18F]FET and [18F]FMISO) to see if the imaging results will help with the placement of catheters for…
- Trial name
- NCT07778979
- Testing
- [18F]FMISO-PET with contrast-enhanced MRI
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of Alabama at Birmingham
Glioma, Malignant Glioma
FDOPA-PET/MRI for the Pre-operative Evaluation of Gliomas
This is a pilot study designed to evaluate the potential of using FDOPA-PET/MRI for improving surgical planning and providing non-invasive prognostic information in patients with gliomas that have substantial non-enhancing…
- Trial name
- NCT02371031
- Testing
- 6-[F-18]-Fluoro-L-3,4,-dihydroxyphenylalanine, PET/MRI, Surgical resection (standard of care)
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Washington University School of Medicine
Obesity, Morbid, Insulin Resistance
Effects of Morbid Obesity and Bariatric Surgery on Brain Inflammation, Insulin Resistance and Central Reward System
Background: Morbid obesity is associated with decreased brain µ-opioid receptor availability, possibly resulting in higher food intake needed to gain pleasure from eating.
- Trial name
- BariBrainPET (NCT05080205)
- Testing
- Bariatric surgery
- Where
- Finland
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Turku University Hospital
Obesity
A Study in People With Obesity to Test the Effects of BI 456906 Compared With Semaglutide on Glucagon Receptor Activity in the Liver
This study is open to adults with obesity. People with a body mass index (BMI) in the range from 30 to 40 kg/m2 and a body weight of 70 to 150 kg can participate in the study.
- Trial name
- NCT05202353
- Testing
- BI 456906, Semaglutide
- Where
- Netherlands
- Volunteers
- 29 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim